Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DONUT: Atropine for Pre-Myopia Compliance
NCT06029530Phase 1Withdrawn
- Sponsor
- The Ohio State University
- Start
- Jan 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 1, randomised trial of NVK002 in myopia (3 arms), sponsored by The Ohio State University. Primary endpoint: Compliance percentage at 30 days. Planned start Jan 2024; status: withdrawn.
02
Drugs
NVK002
03
Conditions
myopia
Beyond the preview
Go deeper on NCT06029530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029530.